Harvard Bioscience Inc (HBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Harvard Bioscience Inc (HBIO) has a cash flow conversion efficiency ratio of 0.059x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($830.00K) by net assets ($14.07 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Harvard Bioscience Inc - Cash Flow Conversion Efficiency Trend (1999–2024)
This chart illustrates how Harvard Bioscience Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Harvard Bioscience Inc for a breakdown of total debt and financial obligations.
Harvard Bioscience Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Harvard Bioscience Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
U.C.A. AG O.N.
F:UCA1
|
N/A |
|
Canadian North Resources Inc.
V:CNRI
|
-0.008x |
|
Hankook Cosmetics Manufacturing Co Ltd
KO:003350
|
0.139x |
|
Grand Kartech Tbk
JK:KRAH
|
0.061x |
|
Seker Finansal Kiralama AS
IS:SEKFK
|
0.281x |
|
Rubicon Organics Inc
V:ROMJ
|
0.010x |
|
Murray International Trust
LSE:MYI
|
0.025x |
|
Aasen Sparebank
OL:AASB
|
0.017x |
Annual Cash Flow Conversion Efficiency for Harvard Bioscience Inc (1999–2024)
The table below shows the annual cash flow conversion efficiency of Harvard Bioscience Inc from 1999 to 2024. For the full company profile with market capitalisation and key ratios, see HBIO company net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $63.34 Million | $1.44 Million | 0.023x | -88.16% |
| 2023-12-31 | $73.07 Million | $14.03 Million | 0.192x | +1103.48% |
| 2022-12-31 | $72.22 Million | $1.15 Million | 0.016x | +5.42% |
| 2021-12-31 | $83.40 Million | $1.26 Million | 0.015x | -87.56% |
| 2020-12-31 | $76.68 Million | $9.33 Million | 0.122x | +23.54% |
| 2019-12-31 | $81.69 Million | $8.05 Million | 0.099x | +245.36% |
| 2018-12-31 | $82.18 Million | $2.34 Million | 0.029x | +118.30% |
| 2017-12-31 | $80.90 Million | $1.06 Million | 0.013x | -82.48% |
| 2016-12-31 | $72.20 Million | $5.38 Million | 0.075x | +720.68% |
| 2015-12-31 | $77.60 Million | $705.00K | 0.009x | -80.07% |
| 2014-12-31 | $95.47 Million | $4.35 Million | 0.046x | +6.06% |
| 2013-12-31 | $94.48 Million | $4.06 Million | 0.043x | -44.46% |
| 2012-12-31 | $104.21 Million | $8.06 Million | 0.077x | +16.38% |
| 2011-12-31 | $95.50 Million | $6.35 Million | 0.066x | -51.20% |
| 2010-12-31 | $90.25 Million | $12.29 Million | 0.136x | -37.91% |
| 2009-12-31 | $75.26 Million | $16.51 Million | 0.219x | +59.05% |
| 2008-12-31 | $66.72 Million | $9.20 Million | 0.138x | -15.18% |
| 2007-12-31 | $74.14 Million | $12.05 Million | 0.163x | +39.88% |
| 2006-12-31 | $71.88 Million | $8.36 Million | 0.116x | +53.09% |
| 2005-12-31 | $68.42 Million | $5.20 Million | 0.076x | -30.72% |
| 2004-12-31 | $104.36 Million | $11.44 Million | 0.110x | +434.44% |
| 2003-12-31 | $98.88 Million | $2.03 Million | 0.021x | +126.72% |
| 2002-12-31 | $88.38 Million | $799.46K | 0.009x | -85.24% |
| 2001-12-31 | $66.81 Million | $4.10 Million | 0.061x | +49.49% |
| 2000-12-31 | $52.33 Million | $2.15 Million | 0.041x | -88.81% |
| 1999-12-31 | $7.98 Million | $2.93 Million | 0.367x | -- |
About Harvard Bioscience Inc
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equ… Read more